Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00731003
NCT00731003CompletedNot Applicable

The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and IBS Patients

Maastricht University Medical Center1 site in 1 country60 target enrollmentStarted: April 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
60
Locations
1
Primary Endpoint
The primary aim is to assess intestinal permeability under altered serotonergic conditions by means of sugar permeability test
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Serotonin, 5-hydroxytryptamin (5-HT), plays an important role in regulating the gastrointestinal functions. In this study we will modulate the serotonin system with acute tryptophan depletion (ATD) and administration of 5-hydroxytryptophan (5-HTP). ATD is based on ingestion of an amino acid drink devoid of the precursor of serotonin and hence caused a decreased serotonin level. 5-hydroxy-tryptophan is the direct precursor of serotonin and its administration, an increased serotonin level is expected. During these interventions, gut permeability and visceral sensitivity will be measured in healthy individuals and patients with irritable bowel syndrome, which is characterized by altered permeability and visceral hypersensitivity.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •IBS-patients
  • •Inclusion criteria:
  • •IBS will be diagnosed according to the Rome III criteria* [35]:
  • •Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following:
  • •Improvement with defecation
  • •Onset associated with a change in frequency of stool
  • •Onset associated with a change in form (appearance) of stool
  • •Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
  • •Discomfort means an uncomfortable sensation not described as pain. In pathophysiological research and clinical trails, a pain/discomfort frequency of at least 2 days a week during screening evaluation is an indication for subject's eligibility.
  • •Based on the medical history and previous examination, no other causes for the abdominal complaints can be defined.
  • •Age between 18 and 65 years
  • •Healthy individuals
  • •Inclusion criteria:
  • •All subjects will be screened with a standardized psychiatric examination using the mini international neuropsychiatric interview (MINI) to determine present psychiatric state. General psychological state will be assessed using the 17 item Hamilton depression rating scale (HAM-D17), the Dutch version of the symptom checklist (SCL-90) and the hospital anxiety and depression rating scale (HADS). The psychiatric evaluation will be carried out by a psychiatrist. Volunteers with deviating scores on any topic will be excluded from participation.
  • •Healthy individuals between age 18 and 65 years will be included in the study.

Exclusion Criteria

  • •Exclusion criteria for IBS patients:
  • •Severe co-morbidity hindering a rectal barostat procedure, according to the gastroenterologist's perception.
  • •Abdominal surgery, except for uncomplicated appendectomy, laparoscopic cholecystectomy or hysterectomy.
  • •Inability to stop medication that can influence gastrointestinal motility or perception (like loperamide, butylscopolamine, psylliumsead (metamucil), duspatal, metoclopramide, domperidon, erytromycine), or serotonin metabolism (carbidopa) for at least 3 days before tests.
  • •History of psychiatric disorders including use of psychoactive medication or psychological symptomatology, defined as a diagnosis on the MINI, HAM-D17 score above 18, global severity index score on SCL-90 for females ≥150, for males ≥131, or HADS scores ≥
  • •First-degree family members with psychiatric disorders
  • •Administration of investigational drugs in the 180 days prior to the study
  • •Premenstrual syndrome, dieting, pregnancy, lactation
  • •Excessive alcohol consumption (>20 alcoholic consumption per week)
  • •Blood donation within 3 months before the study period
  • •Self-admitted HIV-positive state
  • •Irregular day-night rhythm
  • •Exclusion criteria for healthy individuals:
  • •History of gastrointestinal, psychiatric disorders including use of psychoactive medication or psychological symptomatology, defined as a diagnosis on the MINI, HAM-D17 score above 18, global severity index score on SCL-90 for females ≥150, for males ≥131, or HADS scores ≥ 8 First-degree family members with psychiatric disorders
  • •Use of medication, except oral contraceptives, within 14 days prior to testing
  • •Administration of investigational drugs in the 180 days prior to the study
  • •Previous abdominal surgery (other than uncomplicated appendectomy, laparoscopic cholecystectomy and hysterectomy)
  • •Premenstrual syndrome, dieting, pregnancy, lactation
  • •Excessive alcohol consumption (>20 alcoholic consumption per week)
  • •Blood donation within 3 months before the study period
  • •Self-admitted HIV-positive state
  • •Irregular day-night rhythm
  • •Severe co-morbidity hindering a rectal barostat procedure, according to the gastroenterologist's perception.

Arms & Interventions

I

Experimental

ATD procedure

Intervention: Acute tryptophan depletion (Other)

II

Experimental

Oxitriptan

Intervention: Oxitriptan (Drug)

III

Placebo Comparator

Amino acid mixture with tryptophan

Intervention: Amino acid drink with tryptophan (Other)

IV

Placebo Comparator

Placebo capsule

Intervention: Placebo capsule (Drug)

Outcomes

Primary Outcomes

The primary aim is to assess intestinal permeability under altered serotonergic conditions by means of sugar permeability test

Time Frame: 2010

Secondary Outcomes

  • To assess tight junction functionality and serotonin metabolism To assess visceral hypersensitivity under altered serotoninergic conditions To examine biopsy specimens for serotonergic and intestinal permeability parameters in ex vivo circumstances(2010)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
The effect of serotonergic modulation on intestinal permeability and visceral perception in healthy individuals and IBS patientsfunctional gastrointestinal disorder10017977irritable bowel syndrome
NL-OMON33644niversiteit Maastricht60
Recruiting
Not Applicable
Investigating Serotonin Signalling in IBD PatientsInflammatory Bowel Disease
NCT01650311McMaster University60
Active, not recruiting
Not Applicable
Effect of Serotonergic Stimulation on the Gut-brain AxisHealthyIrritable Bowel Syndrome
NCT03920410Örebro University, Sweden58
Recruiting
Phase 2
Effects of 5HTP on the Injured Human Spinal CordSpinal Cord Injuries
NCT04520178University of Alberta30
Terminated
Not Applicable
Serotonin Role on Brain Circuits Involved in Food Avoidance in Anorexia NervosaAnorexia Nervosa
NCT05155280Centre Hospitalier Universitaire de Saint Etienne57
The Effect of Serotonergic Modulation on... | Clinical Trial